RU2505311C2 - Пролонгированная доставка аналогов компстатина из гелей - Google Patents

Пролонгированная доставка аналогов компстатина из гелей Download PDF

Info

Publication number
RU2505311C2
RU2505311C2 RU2010113513/15A RU2010113513A RU2505311C2 RU 2505311 C2 RU2505311 C2 RU 2505311C2 RU 2010113513/15 A RU2010113513/15 A RU 2010113513/15A RU 2010113513 A RU2010113513 A RU 2010113513A RU 2505311 C2 RU2505311 C2 RU 2505311C2
Authority
RU
Russia
Prior art keywords
compstatin
compstatin analog
liquid composition
analog
seq
Prior art date
Application number
RU2010113513/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2010113513A (ru
Inventor
Седрик ФРАНСУА
Паскаль ДЕШАТЕЛЕТС
Пол ОЛСОН
Original Assignee
Потентия Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Потентия Фармасьютикалз, Инк. filed Critical Потентия Фармасьютикалз, Инк.
Publication of RU2010113513A publication Critical patent/RU2010113513A/ru
Application granted granted Critical
Publication of RU2505311C2 publication Critical patent/RU2505311C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2010113513/15A 2007-10-02 2008-10-02 Пролонгированная доставка аналогов компстатина из гелей RU2505311C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US97691907P 2007-10-02 2007-10-02
US60/976,919 2007-10-02
US2646008P 2008-02-05 2008-02-05
US61/026,460 2008-02-05
PCT/US2008/078593 WO2009046198A2 (en) 2007-10-02 2008-10-02 Sustained delivery of compstatin analogs from gels

Publications (2)

Publication Number Publication Date
RU2010113513A RU2010113513A (ru) 2011-11-10
RU2505311C2 true RU2505311C2 (ru) 2014-01-27

Family

ID=40526950

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010113513/15A RU2505311C2 (ru) 2007-10-02 2008-10-02 Пролонгированная доставка аналогов компстатина из гелей

Country Status (12)

Country Link
US (1) US20110182877A1 (enExample)
EP (1) EP2207530A4 (enExample)
JP (1) JP2010540654A (enExample)
KR (2) KR20150080007A (enExample)
CN (1) CN101854916A (enExample)
AU (1) AU2008308657A1 (enExample)
BR (1) BRPI0817524A2 (enExample)
CA (1) CA2701470A1 (enExample)
MX (1) MX2010003630A (enExample)
RU (1) RU2505311C2 (enExample)
WO (1) WO2009046198A2 (enExample)
ZA (1) ZA201002365B (enExample)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2661621C2 (ru) * 2016-12-19 2018-07-17 Александр Николаевич Епихин Способ пролонгации и усиления терапевтического эффекта действия ингибиторов ангиогенеза при лечении неоваскулярных форм макулярных дегенераций
RU2733720C2 (ru) * 2015-12-16 2020-10-06 Ра Фармасьютикалз, Инк. Модуляторы активности комплемента
US10918691B2 (en) 2015-01-28 2021-02-16 Ra Pharmaceuticals, Inc. Modulators of complement activity
US11014965B2 (en) 2014-06-12 2021-05-25 Ra Pharmaceuticals, Inc. Modulation of complement activity
US11040107B2 (en) 2017-04-07 2021-06-22 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
US11123399B2 (en) 2016-12-07 2021-09-21 Ra Pharmaceuticals, Inc. Modulators of complement activity
US11903994B2 (en) 2015-10-07 2024-02-20 Apellis Pharmaceuticals, Inc. Dosing regimens
US12290566B2 (en) 2017-12-15 2025-05-06 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
US12558398B2 (en) 2019-06-04 2026-02-24 Ucb Holdings, Inc. Inflammatory disease treatment with complement inhibitors

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
US20110092446A1 (en) * 2007-07-20 2011-04-21 Cedric Francois Compositions and methods for treatment of trauma
WO2009121065A2 (en) * 2008-03-28 2009-10-01 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
TWI492769B (zh) 2009-09-23 2015-07-21 Alcon Res Ltd 可注射的水性眼用組成物及其使用之方法
US9421240B2 (en) 2010-06-22 2016-08-23 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
US9107822B2 (en) 2010-09-03 2015-08-18 Santen Sas Water-in oil type emulsion for treating a disease of the eye
NZ607103A (en) 2010-09-03 2015-09-25 Santen Sas A water-in-oil type emulsion for treating a disease of the eye
EP2425814B1 (en) 2010-09-03 2013-06-19 Novagali Pharma S.A. A water-in-oil type emulsion for treating a disease of the eye
RU2653439C9 (ru) 2011-05-11 2018-10-16 Апеллис Фармасьютикалс, Инк. Клеточно-реактивные аналоги компстатина, аналоги компстатина длительного действия или аналоги компстатина нацеленного действия и их применение
CA2840270C (en) * 2011-06-22 2023-09-26 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
WO2014028861A1 (en) * 2012-08-17 2014-02-20 Apellis Pharmaceuticals, Inc. Detection of high risk drusen
US10035822B2 (en) 2012-11-15 2018-07-31 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
US9940683B2 (en) 2013-07-31 2018-04-10 Elwha Llc Managing a risk of a liability that is incurred if a subject treated for a condition is retreated within a specified time period
US20150039337A1 (en) * 2013-07-31 2015-02-05 Elwha Llc Managing a risk of a liability that is incurred if one or more subjects each treated for a respective condition are retreated within a respective specified time period
EP2918262B1 (en) 2014-03-10 2023-08-09 PLS-Design GmbH Induction of antigen-specific tolerance by peripheral phagocytosis
US20180228811A1 (en) * 2014-12-12 2018-08-16 The Schepens Eye Research Institute, Inc. Gdnf induction for the treatment of retinal disorders
EP3095440B1 (en) 2015-05-19 2020-01-15 PLS-Design GmbH Antigen-specific immunotherapy using tolerizing liposomes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007044668A2 (en) * 2005-10-08 2007-04-19 Potentia Pharmaceuticals, Inc. Compstatin and analogs thereof for eye disorders
US20070149616A1 (en) * 2005-12-22 2007-06-28 Alcon Manufacturing, Ltd. C3-Convertase Inhibitors for the Prevention and Treatment of Age-Related Macular Degeneration in Patients With At Risk Variants Of Complement Factor H

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7488590B2 (en) * 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US7989589B2 (en) * 2002-09-20 2011-08-02 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved activity
US8168584B2 (en) * 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
ES2390828T3 (es) * 2005-11-28 2012-11-16 The Trustees Of The University Of Pennsylvania Análogos potentes de la compstatina
US20070196367A1 (en) * 2006-02-22 2007-08-23 Valentin Dinu Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
EP2148691B1 (en) * 2007-02-05 2015-05-20 Apellis Pharmaceuticals, Inc. Compstatin analogues for use in the treatment of inflammatory conditions of the respiratory system

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007044668A2 (en) * 2005-10-08 2007-04-19 Potentia Pharmaceuticals, Inc. Compstatin and analogs thereof for eye disorders
US20070149616A1 (en) * 2005-12-22 2007-06-28 Alcon Manufacturing, Ltd. C3-Convertase Inhibitors for the Prevention and Treatment of Age-Related Macular Degeneration in Patients With At Risk Variants Of Complement Factor H

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Arvind Sahu et al " Compstatin , peptide inhibitor of complement, exhibits species-specific binding to complement component C3", Molecular Immunology, 2003, 39, 557-566. *
Onoue S et al "Structural transition of glucagon in the concentrated solution observed by electrophoretic and spectroscopic techniques", J Chromatogr A, 2006, Mar 24; 1109(2): 167-73, Epub 2005 dec 20, PMID: 16364337 , реферат. *
Onoue S et al "Structural transition of glucagon in the concentrated solution observed by electrophoretic and spectroscopic techniques", J Chromatogr A, 2006, Mar 24; 1109(2): 167-73, Epub 2005 dec 20, PMID: 16364337 , реферат. Arvind Sahu et al " Compstatin , peptide inhibitor of complement, exhibits species-specific binding to complement component C3", Molecular Immunology, 2003, 39, 557-566. *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11014965B2 (en) 2014-06-12 2021-05-25 Ra Pharmaceuticals, Inc. Modulation of complement activity
US11535650B1 (en) 2014-06-12 2022-12-27 Ra Pharmaceuticals, Inc. Modulation of complement activity
US11965040B2 (en) 2014-06-12 2024-04-23 Ra Pharmaceuticals, Inc. Modulation of complement activity
US10918691B2 (en) 2015-01-28 2021-02-16 Ra Pharmaceuticals, Inc. Modulators of complement activity
US12239684B2 (en) 2015-01-28 2025-03-04 Ra Pharmaceuticals, Inc. Modulators of complement activity
US11707503B2 (en) 2015-01-28 2023-07-25 Ra Pharmaceuticals, Inc. Modulators of complement activity
US11903994B2 (en) 2015-10-07 2024-02-20 Apellis Pharmaceuticals, Inc. Dosing regimens
US12528836B2 (en) 2015-10-07 2026-01-20 Apellis Pharmaceuticals, Inc. Dosing regimens
RU2733720C2 (ru) * 2015-12-16 2020-10-06 Ра Фармасьютикалз, Инк. Модуляторы активности комплемента
US10835574B2 (en) 2015-12-16 2020-11-17 Ra Pharmaceuticals, Inc. Modulators of complement activity
RU2769701C2 (ru) * 2015-12-16 2022-04-05 Ра Фармасьютикалз, Инк. Модуляторы активности комплемента
US11752190B2 (en) 2015-12-16 2023-09-12 Ra Pharmaceuticals, Inc. Modulators of complement activity
US11723949B2 (en) 2016-12-07 2023-08-15 Ra Pharmaceuticals, Inc. Modulators of complement activity
US11123399B2 (en) 2016-12-07 2021-09-21 Ra Pharmaceuticals, Inc. Modulators of complement activity
RU2661621C2 (ru) * 2016-12-19 2018-07-17 Александр Николаевич Епихин Способ пролонгации и усиления терапевтического эффекта действия ингибиторов ангиогенеза при лечении неоваскулярных форм макулярных дегенераций
US11844841B2 (en) 2017-04-07 2023-12-19 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
US11040107B2 (en) 2017-04-07 2021-06-22 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
US12290566B2 (en) 2017-12-15 2025-05-06 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
US12458695B2 (en) 2017-12-15 2025-11-04 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
US12558398B2 (en) 2019-06-04 2026-02-24 Ucb Holdings, Inc. Inflammatory disease treatment with complement inhibitors

Also Published As

Publication number Publication date
WO2009046198A3 (en) 2009-07-16
CN101854916A (zh) 2010-10-06
ZA201002365B (en) 2010-12-29
KR20150080007A (ko) 2015-07-08
JP2010540654A (ja) 2010-12-24
EP2207530A2 (en) 2010-07-21
BRPI0817524A2 (pt) 2017-05-02
WO2009046198A2 (en) 2009-04-09
CA2701470A1 (en) 2009-04-09
MX2010003630A (es) 2010-04-21
US20110182877A1 (en) 2011-07-28
RU2010113513A (ru) 2011-11-10
EP2207530A4 (en) 2013-09-11
KR20100094453A (ko) 2010-08-26
AU2008308657A1 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
US20110182877A1 (en) Sustained delivery of compstatin analogs from gels
CN103505718B (zh) 用于眼部病症的补体抑制素和其类似物
US10407466B2 (en) Methods of selecting compstatin mimetics
JP7858722B2 (ja) Ｃ３ｂ結合ポリペプチド
AU2016253654A1 (en) Injectable combination therapy for eye disorders
MX2008004656A (es) Compstatina y analogos de la misma para tratar trastornos oculares
HK1121380A (en) Compstatin and analogs thereof for eye disorders
HK1121380B (en) Compstatin and analogs thereof for eye disorders

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20181003